-+ 0.00%
-+ 0.00%
-+ 0.00%
AVITA Medical Reports Complete 6-Month Cohealyx I Study Results In Full-Thickness Wounds; Study Met Its Primary Endpoint
Share
Listen to the news
  • Six-month follow-up showed continued wound healing and improving scar scores, with no Cohealyx® related adverse events
     
  • Tissue samples collected immediately before skin grafting showed matrix integration of Cohealyx and new tissue formation
     
  • Study met its primary endpoint; median graft readiness was 11 days, with 72% of wounds ready for grafting within two weeks
     

VALENCIA, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH))), a leading therapeutic acute wound care company, today announced complete results, including six-month follow-up, from its Cohealyx I study in patients with full-thickness wounds. The findings extend the previously reported evidence of accelerated wound bed preparation and high surgeon satisfaction, with follow-up showing wound healing, improving scar scores, and no Cohealyx related adverse events. This data was presented at the Northeastern Regional American Burn Association Conference in Boston, MA.

The study met its primary endpoint, demonstrating significantly earlier readiness for skin grafting against the lower bound of a performance goal derived from published studies of other dermal matrices (p<0.001). As reported in April, mean time to graft readiness was 13.6 days, compared with the 28-day performance goal. Median time was 11 days, with 72% of patients ready within two weeks.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending